CardioDx Raises More than $40M in Series E Round | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cardiovascular genomics test firm CardioDx has raised more than $40 million in a Series E financing round.

David Levison, CEO of the Palo Alto, Calif.-based company confirmed to GenomeWeb Daily News that the round raised more than $40 million, but he declined to provide a more exact figure. However, a document filed with the US Securities and Exchange Commission last week claimed the company has brought in $57.5 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."